docetaxel anhydrous has been researched along with Thromboembolism, Venous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonarakis, ES; Brodsky, RA; Park, JC; Pratz, CF; Tesfaye, A | 1 |
| Carducci, MA; Friedman, PN; Halabi, S; Hertz, DL; Jiang, C; Kelley, MJ; Kelly, WK; Mahoney, JF; McLeod, HL; Morris, MJ; Mulkey, FA; Owzar, K; Patel, JN; Ratain, MJ; Small, EJ | 1 |
1 trial(s) available for docetaxel anhydrous and Thromboembolism, Venous
| Article | Year |
|---|---|
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteries; Bevacizumab; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Thromboembolism; Venous Thromboembolism | 2015 |
1 other study(ies) available for docetaxel anhydrous and Thromboembolism, Venous
| Article | Year |
|---|---|
The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Docetaxel; Drug Synergism; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome; Venous Thromboembolism; Warfarin | 2015 |